Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Trading Cabana -- Ignore unavailable to you. Want to Upgrade?

To: ggersh who wrote (5393)	4/28/2009 8:42:07 AM
From: RockyBalboa	Read Replies (1) \| Respond to of 6370

Dendreon could be a total failure, still. Genta 2009, we need one. Well - stay on the bus until it slows down and explodes,... it would fit to a bearish, and scammy market if the FDA sent them packing. Options prices at nosebleed levels. Nearly impossible to trade. On yahoo, it is described as a possible $360 stock. Dr. Robert Reider, a professor of urology at the UCLA Jonsson Comprehensive Cancer Center, is a self-described Provenge skeptic in part because he's uncomfortable that Provenge appears to prolong patient survival without having any measurable effect on the tumor itself. "In all the studies to date, Provenge has not stopped tumors from shrinking, nor has it had any positive effect on a patient's quality of life or PSA scores," said Reider. PSA is a protein marker found in blood used to detect prostate cancer. "There has never been a drug approved that improved survival yet had no impact on the disease itself," Reider added, although he conceded that Provenge may well be the first if the drug posts a strong survival benefit Tuesday afternoon.